SplitCore Technology Allows Efficient Production of Virus-Like Particles Presenting a Receptor-Contacting Epitope of Human IgE

A. Zh Baltabekova, Zh S. Shagyrova, A. S. Kamzina, M. Voykov, Ye Zhiyenbay, E. M. Ramanculov, A. V. Shustov

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Immunoglobulin E (IgE) plays a central role in type I hypersensitivity including allergy and asthma. Novel treatment strategy envisages development of a therapeutic vaccine designed to elicit autologous blocking antibodies against the IgE. We sought to develop an IgE-epitope antigen that induces antibodies against a receptor-contacting epitope on human IgE molecule. We designed the VLP immunogens which utilize hepatitis B virus core protein (HBcAg) as a carrier, and present arrays of the receptor-contacting epitopes of the human IgE on their surfaces. FG loop from the IgE domain Cε3 was engineered into the HBcAg. Two constructs explore a well-established approach of insertion into a main immunodominant region of the HBcAg. Third construct is different in that the carrier is produced in a form of an assembly of two polypeptide chains which upon expression remain associated in a stable VLP-forming subunit (SplitCore technology). No VLPs were isolated from E.coli expressing the IgE-epitope antigens with contiguous sequences. On the contrary, the SplitCore antigen carrying the FG loop efficiently formed the VLPs. Immunization of mice with the VLPs presenting receptor-contacting epitope of the IgE elicited antibodies recognizing the human IgE in ELISA.

Original languageEnglish
Pages (from-to)746-755
Number of pages10
JournalMolecular Biotechnology
Volume57
Issue number8
DOIs
Publication statusPublished - Apr 3 2015

Fingerprint

Epitopes
Viruses
Virion
Immunoglobulin E
Technology
Antigens
Antibodies
Hepatitis B Core Antigens
Allergies
Immunization
Vaccines
Polypeptides
Escherichia coli
Viral Core Proteins
Immediate Hypersensitivity
Immunodominant Epitopes
Blocking Antibodies
Proteins
Hepatitis B virus
Molecules

Keywords

  • Allergy
  • Hepatitis B capsid protein
  • Immunoglobulin E
  • SplitCore
  • Therapeutic vaccine
  • Virus-like particles

ASJC Scopus subject areas

  • Biochemistry
  • Biotechnology
  • Molecular Biology
  • Bioengineering
  • Applied Microbiology and Biotechnology

Cite this

SplitCore Technology Allows Efficient Production of Virus-Like Particles Presenting a Receptor-Contacting Epitope of Human IgE. / Baltabekova, A. Zh; Shagyrova, Zh S.; Kamzina, A. S.; Voykov, M.; Zhiyenbay, Ye; Ramanculov, E. M.; Shustov, A. V.

In: Molecular Biotechnology, Vol. 57, No. 8, 03.04.2015, p. 746-755.

Research output: Contribution to journalArticle

Baltabekova, A. Zh ; Shagyrova, Zh S. ; Kamzina, A. S. ; Voykov, M. ; Zhiyenbay, Ye ; Ramanculov, E. M. ; Shustov, A. V. / SplitCore Technology Allows Efficient Production of Virus-Like Particles Presenting a Receptor-Contacting Epitope of Human IgE. In: Molecular Biotechnology. 2015 ; Vol. 57, No. 8. pp. 746-755.
@article{8600fc388c744e4cba4e036d305284ae,
title = "SplitCore Technology Allows Efficient Production of Virus-Like Particles Presenting a Receptor-Contacting Epitope of Human IgE",
abstract = "Immunoglobulin E (IgE) plays a central role in type I hypersensitivity including allergy and asthma. Novel treatment strategy envisages development of a therapeutic vaccine designed to elicit autologous blocking antibodies against the IgE. We sought to develop an IgE-epitope antigen that induces antibodies against a receptor-contacting epitope on human IgE molecule. We designed the VLP immunogens which utilize hepatitis B virus core protein (HBcAg) as a carrier, and present arrays of the receptor-contacting epitopes of the human IgE on their surfaces. FG loop from the IgE domain Cε3 was engineered into the HBcAg. Two constructs explore a well-established approach of insertion into a main immunodominant region of the HBcAg. Third construct is different in that the carrier is produced in a form of an assembly of two polypeptide chains which upon expression remain associated in a stable VLP-forming subunit (SplitCore technology). No VLPs were isolated from E.coli expressing the IgE-epitope antigens with contiguous sequences. On the contrary, the SplitCore antigen carrying the FG loop efficiently formed the VLPs. Immunization of mice with the VLPs presenting receptor-contacting epitope of the IgE elicited antibodies recognizing the human IgE in ELISA.",
keywords = "Allergy, Hepatitis B capsid protein, Immunoglobulin E, SplitCore, Therapeutic vaccine, Virus-like particles",
author = "Baltabekova, {A. Zh} and Shagyrova, {Zh S.} and Kamzina, {A. S.} and M. Voykov and Ye Zhiyenbay and Ramanculov, {E. M.} and Shustov, {A. V.}",
year = "2015",
month = "4",
day = "3",
doi = "10.1007/s12033-015-9867-0",
language = "English",
volume = "57",
pages = "746--755",
journal = "Molecular Biotechnology",
issn = "1073-6085",
publisher = "Humana Press",
number = "8",

}

TY - JOUR

T1 - SplitCore Technology Allows Efficient Production of Virus-Like Particles Presenting a Receptor-Contacting Epitope of Human IgE

AU - Baltabekova, A. Zh

AU - Shagyrova, Zh S.

AU - Kamzina, A. S.

AU - Voykov, M.

AU - Zhiyenbay, Ye

AU - Ramanculov, E. M.

AU - Shustov, A. V.

PY - 2015/4/3

Y1 - 2015/4/3

N2 - Immunoglobulin E (IgE) plays a central role in type I hypersensitivity including allergy and asthma. Novel treatment strategy envisages development of a therapeutic vaccine designed to elicit autologous blocking antibodies against the IgE. We sought to develop an IgE-epitope antigen that induces antibodies against a receptor-contacting epitope on human IgE molecule. We designed the VLP immunogens which utilize hepatitis B virus core protein (HBcAg) as a carrier, and present arrays of the receptor-contacting epitopes of the human IgE on their surfaces. FG loop from the IgE domain Cε3 was engineered into the HBcAg. Two constructs explore a well-established approach of insertion into a main immunodominant region of the HBcAg. Third construct is different in that the carrier is produced in a form of an assembly of two polypeptide chains which upon expression remain associated in a stable VLP-forming subunit (SplitCore technology). No VLPs were isolated from E.coli expressing the IgE-epitope antigens with contiguous sequences. On the contrary, the SplitCore antigen carrying the FG loop efficiently formed the VLPs. Immunization of mice with the VLPs presenting receptor-contacting epitope of the IgE elicited antibodies recognizing the human IgE in ELISA.

AB - Immunoglobulin E (IgE) plays a central role in type I hypersensitivity including allergy and asthma. Novel treatment strategy envisages development of a therapeutic vaccine designed to elicit autologous blocking antibodies against the IgE. We sought to develop an IgE-epitope antigen that induces antibodies against a receptor-contacting epitope on human IgE molecule. We designed the VLP immunogens which utilize hepatitis B virus core protein (HBcAg) as a carrier, and present arrays of the receptor-contacting epitopes of the human IgE on their surfaces. FG loop from the IgE domain Cε3 was engineered into the HBcAg. Two constructs explore a well-established approach of insertion into a main immunodominant region of the HBcAg. Third construct is different in that the carrier is produced in a form of an assembly of two polypeptide chains which upon expression remain associated in a stable VLP-forming subunit (SplitCore technology). No VLPs were isolated from E.coli expressing the IgE-epitope antigens with contiguous sequences. On the contrary, the SplitCore antigen carrying the FG loop efficiently formed the VLPs. Immunization of mice with the VLPs presenting receptor-contacting epitope of the IgE elicited antibodies recognizing the human IgE in ELISA.

KW - Allergy

KW - Hepatitis B capsid protein

KW - Immunoglobulin E

KW - SplitCore

KW - Therapeutic vaccine

KW - Virus-like particles

UR - http://www.scopus.com/inward/record.url?scp=84937970597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937970597&partnerID=8YFLogxK

U2 - 10.1007/s12033-015-9867-0

DO - 10.1007/s12033-015-9867-0

M3 - Article

VL - 57

SP - 746

EP - 755

JO - Molecular Biotechnology

JF - Molecular Biotechnology

SN - 1073-6085

IS - 8

ER -